AURA
- Aura Biosciences, Inc.
()
Overview
Company Summary
Aura Biosciences, Inc. is a biopharmaceutical company that focuses on developing novel therapies for the treatment of cancer. The company specializes in the field of viral nanoparticle conjugates (VNCs), which are a type of drug platform that can target and destroy cancer cells while sparing healthy tissues.
Aura Biosciences utilizes a proprietary technology known as the Virus-Like Particle (VLP) platform to engineer VNCs. These VNCs are designed to selectively bind to cancer cells through specific receptors, delivering a potent payload directly to the tumor cells.
The VNC therapy developed by Aura Biosciences has the potential to overcome the limitations of traditional cancer treatments by precisely targeting cancer cells and inducing cell death within them. This approach can minimize damage to healthy tissues and reduce the side effects typically associated with chemotherapy or radiation therapy.
The company's lead product candidate is called AU-011, which is being developed for the treatment of ocular melanoma, a rare and aggressive type of eye cancer. AU-011 harnesses the power of VNCs to selectively kill cancer cells within the eye, preserving vision while effectively treating the disease.
Aura Biosciences is committed to advancing its research and development programs to expand the applications of its proprietary technology beyond ocular melanoma, potentially addressing various types of cancer. By developing targeted therapies that can deliver highly potent drugs directly to cancer cells, the company aims to revolutionize cancer treatment and improve patient outcomes.